On May 12, 2022 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its first quarter 2022 results (Press release, Targovax, MAY 12, 2022, View Source [SID1234614265]). Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1Q 2022 HIGHLIGHTS
Business Development
Announced two key collaboration agreements with Agenus:
Free drug supply of two checkpoint inhibitors for ONCOS-102 combination therapy in the upcoming phase 2 melanoma trial
Inclusion of the adjuvant QS-21 STIMULONTM as an immune-stimulatory component of the TG mutant KRAS cancer vaccine
R&D
Announced that Oslo University Hospital will sponsor a study to test the TG01 cancer vaccine in RAS mutant multiple myeloma patients
Announced a research collaboration with Prof Michael Uhlin at Karolinska Institutet in Stockholm for development and characterization of NextGen circular RNA ONCOS viruses
Organization
Appointed circular RNA co-discoverer and pioneer Dr Thomas B Hansen as VP of Research to lead the circular RNA pipeline program
Strengthened the management team with the appointment of industry veteran Dr Lubor Gaal as Chief Financial Officer
Appointed Dr Raphael Clynes and Mr Thomas Falck as new members of the Board of Directors